Vericel Corporation
VCEL · Nasdaq · United States
Share price · VCEL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VCEL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Nov 2026+13.9%
- 4 Nov 2026+10.7%
Nothing announced by VCEL that day or the session before.
- 30 Oct 2026-6.2%
Nothing announced by VCEL that day or the session before.
- 28 Oct 2026-5.0%
Nothing announced by VCEL that day or the session before.
- 22 Oct 2026+5.0%
- 10 Aug 2026-2.5%
Nothing announced by VCEL that day or the session before.
- 2 Jun 2026+5.0%
Nothing announced by VCEL that day or the session before.
- 29 Apr 2026-6.2%
Nothing announced by VCEL that day or the session before.
- 21 Apr 2026-6.0%
Nothing announced by VCEL that day or the session before.
- 2 Apr 2026+4.9%
Share of unusual movement by asset
For each asset, the share of VCEL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 25% |
| Sessions with no dated event | — | 75% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | —Cell therapy | Cartilage Defects of the Knee |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2030 (2)
February 2030 (1)
What to watch
July 2030 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $85M | $6.9M | $133M+ $37M short-term inv. | —$18M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $77M | $7.5M | $125M+ $37M short-term inv. | —$16M operating cash flow | report ↗ |
| 2026-Q1 | $68M | $8.1M | $109M+ $36M short-term inv. | $6.3M$16M operating cash flow | report ↗ |
| 2025-Q3 | $68M | $6.3M | $100M+ $35M short-term inv. | —$22M operating cash flow | report ↗ |
| 2025-Q2 | $63M | $6.7M | $81M+ $36M short-term inv. | $0.6M$8.2M operating cash flow | report ↗ |
| 2025-Q1 | $53M | $7.3M | $80M+ $39M short-term inv. | $11M$6.6M operating cash flow | report ↗ |
| 2024-Q3 | $58M | $6.1M | $70M+ $48M short-term inv. | $0.9M$10M operating cash flow | report ↗ |
| 2024-Q2 | $53M | $7.4M | $76M+ $52M short-term inv. | $4.7M$19M operating cash flow | report ↗ |
| 2024-Q1 | $51M | $6.4M | $71M+ $48M short-term inv. | $3.9M$7.2M operating cash flow | report ↗ |
| 2023-Q3 | $46M | $5.7M | $84M+ $45M short-term inv. | $3.7M$7.2M operating cash flow | report ↗ |
| 2023-Q2 | $46M | $5.3M | $71M+ $55M short-term inv. | $5.0M$10M operating cash flow | report ↗ |
| 2023-Q1 | $41M | $5.2M | $62M+ $57M short-term inv. | $7.5M$7.9M operating cash flow | report ↗ |
| 2022-Q3 | $38M | $5.0M | $65M+ $46M short-term inv. | $6.6M$4.1M operating cash flow | report ↗ |
| 2022-Q2 | $37M | $4.8M | $62M+ $45M short-term inv. | $9.0M$3.1M operating cash flow | report ↗ |
| 2022-Q1 | $36M | $4.9M | $62M+ $45M short-term inv. | $7.1M$3.5M operating cash flow | report ↗ |
| 2021-Q3 | $34M | $4.3M | $55M+ $44M short-term inv. | $4.9M$3.6M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $276M | $28M | $100M+ $37M short-term inv. | —$52M operating cash flow | report ↗ |
Vericel reported full-year 2025 revenue of $276.26M, up 16.5% YoY, with R&D spend of $27.56M, up 11.1% YoY. Cash and equivalents stood at $100.09M, and the company posted net income of $16.52M, up 59% YoY. No analyst consensus comparison was provided in the material.
For 2026, management guided to total revenue of $316 to $326 million, MACI revenue of $280 to $286 million, gross margin of approximately 75%, and adjusted EBITDA margin of approximately 27%. The company initiated the MACI Ankle MASCOT clinical study, completed its MACI sales force expansion, and remained on track to begin commercial MACI manufacturing in a new facility in 2026 and to submit a MACI marketing authorization application to the U.K. MHRA in 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $237M | $25M | $85M+ $42M short-term inv. | —$58M operating cash flow | report ↗ |
| 2023-FY | $198M | $21M | $87M+ $40M short-term inv. | $0.8M$35M operating cash flow | report ↗ |
| 2022-FY | $164M | $20M | $51M+ $68M short-term inv. | $4.2M$18M operating cash flow | report ↗ |
| 2021-FY | $153M | $16M | $69M+ $35M short-term inv. | $1.9M$29M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 47 sales ($13.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | SIEGAL JONATHAN · Principal Accounting Officer | Option exercise | 263 | $34.90 | $9K | Form 4 |
| 2026-11-13 | SIEGAL JONATHAN · Principal Accounting Officer | Open-market sale | 263 | $57.78 | $15K | Form 4 |
| 2026-11-13 | SIEGAL JONATHAN · Principal Accounting Officer | Option exercise | 935 | $34.90 | $33K | Form 4 |
| 2026-11-13 | SIEGAL JONATHAN · Principal Accounting Officer | Open-market sale | 935 | $57.62 | $54K | Form 4 |
| 2026-11-13 | SIEGAL JONATHAN · Principal Accounting Officer | Option exercise | 687 | $29.82 | $20K | Form 4 |
| 2026-11-13 | SIEGAL JONATHAN · Principal Accounting Officer | Open-market sale | 687 | $57.80 | $40K | Form 4 |
| 2026-11-13 | SIEGAL JONATHAN · Principal Accounting Officer | Option exercise (derivative) | 263 | — | — | Form 4 |
| 2026-11-13 | SIEGAL JONATHAN · Principal Accounting Officer | Option exercise (derivative) | 935 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 275 reporting institutions held 55.1M shares ($1.7B, 107.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 7,765,344 | $249.8M |
| 2 | STATE STREET CORP | 3,152,130 | $101.4M |
| 3 | Soleus Capital Management, L.P. | 2,549,079 | $82.0M |
| 4 | Conestoga Capital Advisors, LLC | 2,463,312 | $79.2M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,230,756 | $71.8M |
| 6 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1,832,709 | $59.0M |
| 7 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,723,572 | $55.4M |
| 8 | GENEVA CAPITAL MANAGEMENT LLC | 1,646,818 | $53.0M |
| 9 | CONGRESS ASSET MANAGEMENT CO | 1,506,918 | $48.5M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1,254,862 | $40.4M |
| 11 | SG Capital Management LLC | 1,209,287 | $38.9M |
| 12 | BANK OF AMERICA CORP /DE/ | 1,098,771 | $35.3M |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 991,626 | $31.9M |
| 14 | LOOMIS SAYLES & CO L P | 975,447 | $31.4M |
| 15 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 959,207 | $30.9M |